Informations sur le produit
- Ethanaminium, N-(4-(bis(4-(diethylamino)phenyl)methylene)-2,5-cyclohexadien-1-ylidene)-N-ethyl-, (T-4)-tetrachlorozincate(2-) (2:1)
- Zincate(2-), tetrachloro-, (T-4)-, bis[N-[4-[bis[4-(diethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium]
- (4-(Bis(4-(diethylamino)phenyl)methylene)-2,5-cyclohexadien-1-ylidene)diethylammonium tetrachlorozincate
Ethyl violet G is a pyrazole derivative that binds to matrix metalloproteinases and inhibits their activity. Ethyl violet G has been shown to inhibit the growth of cancer cells by blocking the production of insulin-like growth factor (IGF) and other growth factors. The binding of ethyl violet G to matrix metalloproteinases reduces the degradation rate of collagen, leading to an increase in tumor size. This drug also inhibits the expression of estrogen receptors and progesterone receptors, which are responsible for regulating cell division in breast tissue. Ethyl violet G can be used to enhance ultrasound imaging during breast cancer surgery by increasing the viscosity of blood vessels in the area. This drug has not been evaluated in pregnant women or children.
